Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2005

Primary Completion Date

October 1, 2005

Study Completion Date

December 1, 2005

Conditions

Psoriasis

Interventions

DRUG

CC10004

2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted

Trial Locations (3)

NYU School of Medicine, New York

Mt Sinai School of Medicine, New York

University of Medicine and Dentistry of New Jersey, New Brunswick